Bayland Capital
VC Fund
Beijing, China
Bayland Capital is a leading investment firm with a focus on innovative life science companies globally.
- Total investments:
- 8
- Last investment:
- Lead investor:
- 50%
Last updated:
For AI agents: llms.txt
Industries Bayland Capital invests in
BiotechnologyHealth CareMedicalBiopharmaTherapeutics
Stages Bayland Capital invests in
Series BSeries ASeries CFunding Round
Countries Bayland Capital invests in
ChinaUnited StatesUnited Kingdom
Investment Focus
Industry
- Biotechnology 5 (63%)
- Health Care 4 (50%)
- Medical 3 (38%)
- Biopharma 2 (25%)
- Therapeutics 2 (25%)
Stage
- Series B 4 (50%)
- Series A 2 (25%)
- Series C 1 (13%)
- Funding Round 1 (13%)
Country
- China 4 (50%)
- United States 2 (25%)
- United Kingdom 1 (13%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
Vibrant
|
Vibrant develops an AI drug development platform to focus on building immune system-related drug pipelines. The company will use artificial intelligence algorithms to accelerate the efficiency of drug development in various aspects such as target discovery, drug design, and drug efficacy evaluation; at the same time, the company expects tocontinuously improve the success rate of drug development through sustainable data accumulation and algorithm optimization.It was founded and headed by Dr. Wang Luquan and is based in Guangzhou, Guangdong, China. | $61M / Jan 12, 2026 | |
BridGene Biosciences
|
BridGene Biosciences is a biotechnology company using cutting-edge chemoproteomic technology to discover and develop small molecules. It enables covalent small molecules to perform proteome-wide screening in live cells, which results in highly selective small molecules that drug traditionally undruggable targets. | $28M / Series B / Oct 16, 2025 | |
PAQ Therapeutics
|
PAQ Therapeutics is a biotechnology company pioneering a new approach to restoring health and curing disease through autophagy, the body's most versatile mechanism for natural cellular degradation. | $39M / Series B / May 05, 2025 | |
CN Bio
|
CN Bio Innovations, formerly Zyoxel Ltd, is part of the Hong Kong-based, CN Innovations Holdings Limited (CNI). CN Bio develops human organ-on-a-chip platforms for the testing and development of therapeutics for serious human diseases. The company’s leading organ-on-chip disease model is a full viral lifecycle model of hepatitis B (HBV) based onthe culture of primary human hepatocytes in the company’s proprietary LiverChip® platform. The HBV disease model, which is referred to as Quantum-B®, is currently being deployed in drug discovery and research alliances with a number of leading pharmaceutical and biotech companies.Working closely with academic pioneers in the bio-engineering field, and backed by prestigious grant awards from sponsors including the United States Defence Advanced Research Projects Agency and UK Technology Strategy Board, CN Bio continues to develop next generation organ-on-chips which will improve the quality of life for millions of people around the world by fast tracking breakthrough therapies to market. | $21M / Series B / Apr 23, 2024 | |
|
LePure Biotech
|
Lechun Biology is an enterprise engaged in disposable products and leak detection equipment in the biotechnology and pharmaceutical industries. The company develops and produces disposable biopharmaceutical process equipment and consumables. The products are used for the storage, transportation, filling and leak detection of various samples inbiosimilars, vaccines and other biopharmaceutical processes. The core product is a disposable storage bag. Recently completed B+ round of financing. This round of financing will be mainly used for the development of a number of innovative new products, the establishment of a US R&D center, the integration of the upstream industrial chain, the securing of the supply chain, and the expansion of the R&D market operation team at home and abroad. | Series C / Jan 12, 2023 | |
Lab Direct
|
Lab Direct is a developer of an online supply chain and procurement service platform that helps laboratories and research institutions to directly connect with suppliers and potential partners to get access to necessary equipment and supplies. The company was founded in 2014 and is headquartered in Shanghai, China. | $10M / Series A / Aug 26, 2022 | |
Biortus
|
Wuxi Biortus Biosciences is an innovation-driven contract research organization (CRO) committed to high-quality R&D services in support of drug discovery.To help our clients achieve their drug discovery goals, we have established five world-class research platforms. These are Recombinant Protein Production, Structural Biology (X-rayCrystallography and Cryo-EM), In Vitro Assays and Screening, Medicinal Chemistry, and Process Development. Through the years, our R&D team has developed a number of practical and innovative techniques of which some have already been granted patent. | $31.3M / Series B / Nov 05, 2021 | |
|
Biortus
|
Wuxi Biortus Biosciences is an innovation-driven contract research organization (CRO) committed to high-quality R&D services in support of drug discovery.To help our clients achieve their drug discovery goals, we have established five world-class research platforms. These are Recombinant Protein Production, Structural Biology (X-rayCrystallography and Cryo-EM), In Vitro Assays and Screening, Medicinal Chemistry, and Process Development. Through the years, our R&D team has developed a number of practical and innovative techniques of which some have already been granted patent. | $15M / Series A / Nov 13, 2020 |
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar stage
Recommended lists
Health Care Investors
43,014 investors
Biotech Investors
21,775 investors
Biotechnology Investors
19,370 investors
Medical Investors
18,848 investors
Health Care VC Funds
32,370 investors
Biotech VC Funds
18,864 investors
Biotechnology VC Funds
17,016 investors
Medical VC Funds
16,214 investors
Health Care Investors in United States
21,541 investors
FAQ
What does Bayland Capital invest in?
Bayland Capital invests primarily in Biotechnology, Health Care and Medical startups, most often at Series B and Series A stage. Most of the 8 investments tracked by Shizune back companies in China. The Investment Focus section breaks down every industry, stage and country in the portfolio.
When did Bayland Capital last invest?
The most recent investment recorded for Bayland Capital closed in Jan 2026. Shizune tracks 8 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
